

가 (radioimmunoassay),
 (Hashimoto's thyroiditis), autoAb test system (Immunodiagno-
 (Addison's disease), stic, USA) (immuno-
 (IDDM) 가 가 fluorescence assay),
 (autoimmune polyglandular syndrome) acetylcholine-R-Ab (RSR, England)
 (SLE), (immunoradiometric
 가 analysis) F-
 1997 1 2002 12 uoro HEPANA test (MBL, Japan)
 28 (indirect immunofluorescence test)
 가 , N latex RF (Behring,
 가 Behring Nephelometer
 가 staging Tanner
 가 staging

40 4

FSH가 40 mIU/ml 28 20.1±2.5 (18~24) ,
 27.2±5.9 (18~
 39) .
 14.25±1.77 (11~18)
 20.33±4.21 (15~ 37
 , 21) .
 5 (71.4%)
 2 (8.7%)
 FSH, LH, E2, TSH, prolactin,
 DHEAS , TSH 가
 T3, T4, free T4

ACTH, s-cortisol, 24h

U-cortisol , FSH 84.27±40.58 mIU/ml, LH
 75g OGTT . 18.08±6.63 mIU/ml, E₂ 13.8±11.8 pg/ml ,
 가 , FSH
 , , 69.23±24.7 mIU/ml, LH 25.5±10.96 mIU/ml, E₂
 , , (rheumatic factor) 17.68±13.6 pg/ml

83.3% Z score -1
 antiTPO RIA kit (osteopenia) , 38.9%
 (Beckman coulter, Germany), -2.5 (osteoporosis)
 RIAZENCO TG Ab (Zentech, Belgium) , 85.7%

Table 1. The comparison of hormonal profile and BMD in premature ovarian failure patients

	Primary (n=7)	Secondary (n=23)	p-value
Age*	20.1±2.5	27.2±5.9	0.0001
FSH	84.27±40.58	69.23±24.7	0.2372
LH	18.08±6.63	25.5±10.96	0.1029
E2	13.8±11.8	17.68±13.6	0.5044
BMD	-2.68±1.04	-2.08±0.95	0.181

* significant p<0.05 by independent t-test

-2.5 (Table 1).
가
가
,
(rheumatic factor),
,
6 (21.4%)
, 2
2가, 2 3가
5 (71.4%)
, 3 2가
가 11 (39.3%) 가
가 4 (14.3%), 2 (7.1%),
2 (7.1%), 1 (3.6%),
1 (3.6%)
(Table 2). 가 가
non-toxic multinodular goiter
(Addi-
son's disease)
ACTH, s-cortisol, 24h U-cortisol
가, 3
2 (8.7%) 2 (follicle depletion) (follicle

Table 2. Autoantibodies in premature ovarian failure patients

	Primary (n=7)	Secondary (n=23)	Total (n=30)
Thyroglobulin	5 (71.4%)	6 (28.6%)	11 (39.3%)
Microsomal Ab.	2 (28.6%)	2 (9.5%)	4 (14.3%)
ANA*	1 (14.3%)	1 (4.8%)	2 (7.1%)
RA#	1 (14.3%)	1 (4.8%)	2 (7.1%)
antiSM†	0	1 (4.8%)	1 (3.6%)
Acetylcholin-R‡	0	1 (4.8%)	1 (3.6%)

* ANA: antinuclear antibody

#RA: rheumatic factor

† antiSM: anti-smooth muscle antibody

‡ Acetylcholin-R: anti-acetylcholin receptor antibody

, 2 3
,
40
,
1% , 1 30 1,000
40 100
4
1
2 FSH 가 40 mIU/ml
2
10~20%,
4~18%
40
(promodial follicle)
가
가
2 (8.7%) 2 (follicle depletion) (follicle

- 777-9.
9. Alper MM, Garner PR. Premature ovarian failure: its relationship to autoimmune disease. *Obstet Gynecol* 1985; 66: 27-30.
 10. Conway GS, Davis MC, Kaltsas G, Patel A. Characterization of idiopathic ovarian failure. *Fertil Steril* 1996; 65: 337-41.
 11. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune syndromes. *Medicine* 1981; 60: 355-9.
 12. May ME, Carey RM. Rapid adrenocorticotrophic hormone test in practice. *Am J Med* 1985; 79: 679-84.
 13. Dal Pra C, Chen S, Furmaniak J, Smith BR, Pedini B, Moscon A, et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison's disease. *Eur J Endocrinol* 2003; 148: 565-70.
 14. Miyake T, Sato Y, Takeuchi S. Implications of circulating autoantibodies and peripheral blood lymphocyte subsets for the genesis of premature ovarian failure. *J Reprod Immunol* 1987; 12: 163-71.
 15. Belvisi L, Bombelli F, Sironi L, Doldi N. Organ-specific autoimmunity in patients with premature ovarian failure. *J Endocrinol Invest* 1993; 16: 889-92.
 16. Ishizuka B, Kudo Y, Amemiya A, Yamada H, Matsuda T, Ogata T. Antinuclear antibodies in patients with premature ovarian failure. *Hum Reprod* 1999; 14: 70-5.
 17. Mignot MH, Schoemaker J, Kleingeld M, Rao BR, Drexhage HA. Premature ovarian failure: the association with autoimmunity. *Eur J Obstet Gynecol Reprod Biol* 1989; 30: 59-66.
 18. Blumenfeld Z, Golan D, Halachmi S, Makler A, Peretz BA, Brandes JM, et al. Premature ovarian failure-the prognostic application of autoimmunity on conception after ovulation induction. *Fertil Steril* 1993; 59: 750-5.
-